- Home
- ACHC vs HALO Comparison
ACHC vs HALO Comparison
Compare ACHC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHC
- HALO
- Stock Information
- Founded
- ACHC 2005
- HALO 1998
- Country
- ACHC United States
- HALO United States
- Employees
- ACHC N/A
- HALO N/A
- Industry
- ACHC Medical Specialities
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACHC Health Care
- HALO Health Care
- Exchange
- ACHC Nasdaq
- HALO Nasdaq
- Market Cap
- ACHC 2.1B
- HALO 7.4B
- IPO Year
- ACHC N/A
- HALO N/A
- Fundamental
- Price
- ACHC $25.78
- HALO $49.23
- Analyst Decision
- ACHC Strong Buy
- HALO Buy
- Analyst Count
- ACHC 10
- HALO 9
- Target Price
- ACHC $54.45
- HALO $63.78
- AVG Volume (30 Days)
- ACHC 3.5M
- HALO 2.6M
- Earning Date
- ACHC 05-12-2025
- HALO 05-06-2025
- Dividend Yield
- ACHC N/A
- HALO N/A
- EPS Growth
- ACHC N/A
- HALO 55.40
- EPS
- ACHC 2.04
- HALO 3.76
- Revenue
- ACHC $3,156,417,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- ACHC $7.90
- HALO $24.79
- Revenue Next Year
- ACHC $8.58
- HALO $22.65
- P/E Ratio
- ACHC $13.24
- HALO $13.36
- Revenue Growth
- ACHC 5.48
- HALO 25.64
- 52 Week Low
- ACHC $20.36
- HALO $41.28
- 52 Week High
- ACHC $82.41
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- ACHC 57.20
- HALO 33.26
- Support Level
- ACHC $23.83
- HALO $48.10
- Resistance Level
- ACHC $28.48
- HALO $69.94
- Average True Range (ATR)
- ACHC 1.21
- HALO 3.31
- MACD
- ACHC 0.76
- HALO -1.04
- Stochastic Oscillator
- ACHC 72.98
- HALO 3.96
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.